Sponsored By:

It’s Time to Cash In on This Huge Biotech Winner

NPS Pharmaceuticals has risen 159% since my initial recommendation

   

NPS Pharmaceuticals (NPSP) — I first recommended NPSP on Nov. 26, under $10, as a trade or a long-term buy. This small-cap biotech company develops therapeutics for gastrointestinal and endocrine disorders, as well as neurological diseases.

On Dec. 21, one of its major products, Gattex, was granted FDA approval to treat short bowel syndrome (SBS). And on Wednesday, a survey by Oppenheimer indicated physicians will be recommending Gattex more over the next three years. Oppenheimer raised their target to $28 from $19.

The stock has been a fabulous performer for us, rising 159% since my initial recommendation. But with negative earnings expected to continue and no big news catalysts in sight, I suggest cashing in on this triple-digit percentage winner.

If you own NPSP, sell it for a profit or write options against your position. With the overall market due for a correction, it is time to take profits on big winners.

08 22 13 npsp 300x188 It's Time to Cash In on This Huge Biotech Winner
Click to Enlarge

chart key 300x84 It's Time to Cash In on This Huge Biotech Winner


Article printed from InvestorPlace Media, http://investorplace.com/2013/08/trade-of-the-day-nps-pharmaceuticals-npsp/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.